In this study, we aimed to demonstrate that IL17A depletion represents a new approach to increase the intensity of an antigen‐specific cytotoxic and humoral response and, therefore, the effectiveness of a cancer vaccine applied in the treatment of PDA (Supporting Information Figure S4). The gene discussed is IL17A; the disease is cancer.